Lokivetmab  (Synonyms: Anti-Canine IL31 Recombinant Antibody; CAN34D3-65; PF-06443537)

Lokivetmab (Anti-Canine IL31 Recombinant Antibody) is an anti-canine IL-31 monoclonal antibody. Lokivetmab inhibits IL-31-mediated activation of pruritogenic signals in peripheral sensory neurons and reduces TH2-weighted inflammation. Lokivetmab demonstrates long-term efficacy in controlling pruritus and improving skin lesions in dogs with canine atopic dermatitis (CAD). Lokivetmab can be used for the research of atopic dermatitis (AD) in dogs^[1].

Caninized IgG2 kappa

Caninized

Lokivetmab (2 mg/kg, i.v. injection, every 4-8 weeks, 12 months) shows long-term efficacy in controlling pruritus and improving skin lesions in dogs^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

256353430  [NCBI]

BAH97742

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

147.51 kDa

1533403-95-0

Liquid

Colorless to light yellow

[Lokivetmab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  IgG2-kappa

• 
  Immobilized IL-31 Protein, Canine (HEK293, His, HY-P703718) can bind Lokivetmab. The EC₅₀ for this effect is 59.37 ng/mL.

• [1]. Gober M, et al. Long term use of lokivetmab (Cytopoint®) in atopic dogs. BMC Vet Res. 2025 Mar 26;21(1):203.  [Content Brief]